These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26514420)

  • 21. Development of a subunit vaccine containing recombinant Riemerella anatipestifer outer membrane protein A and CpG ODN adjuvant.
    Chu CY; Liu CH; Liou JJ; Lee JW; Cheng LT
    Vaccine; 2015 Jan; 33(1):92-9. PubMed ID: 25448104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
    Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
    Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
    Verheul AF; Van Gaans JA; Wiertz EJ; Snippe H; Verhoef J; Poolman JT
    Infect Immun; 1993 Jan; 61(1):187-96. PubMed ID: 8418041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
    Cooper CL; Davis HL; Morris ML; Efler SM; Adhami MA; Krieg AM; Cameron DW; Heathcote J
    J Clin Immunol; 2004 Nov; 24(6):693-701. PubMed ID: 15622454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.
    Sheldon EA; Schwartz H; Jiang Q; Giardina PC; Perez JL
    Hum Vaccin Immunother; 2012 Jul; 8(7):888-95. PubMed ID: 22832260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.
    Ruijne N; Lea RA; O'Hallahan J; Oster P; Martin D
    Clin Vaccine Immunol; 2006 Jul; 13(7):797-801. PubMed ID: 16829618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.
    Aaberge IS; Oster P; Helland OS; Kristoffersen AC; Ypma E; Høiby EA; Feiring B; Nøkleby H
    Clin Diagn Lab Immunol; 2005 May; 12(5):599-605. PubMed ID: 15879021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
    Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
    J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
    Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
    J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial.
    Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ
    mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant.
    Kodama S; Abe N; Hirano T; Suzuki M
    Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers.
    Findlow J; Bai X; Findlow H; Newton E; Kaczmarski E; Miller E; Borrow R
    Vaccine; 2015 Jun; 33(29):3322-30. PubMed ID: 26025807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral immune response to the class 3 outer membrane protein during the course of meningococcal disease.
    Guttormsen HK; Wetzler LM; Naess A
    Infect Immun; 1993 Nov; 61(11):4734-42. PubMed ID: 8406872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
    Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
    Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
    Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
    Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.
    Schmiel DH; Moran EE; Keiser PB; Brandt BL; Zollinger WD
    Infect Immun; 2011 Oct; 79(10):4146-56. PubMed ID: 21768280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.